Modafinil Research Overview (also known as Provigil, Modalert, Modvigil, Alertec)
Modafinil is a prescription wakefulness-promoting agent, also called a eugeroic, used primarily to improve alertness in narcolepsy, obstructive sleep apnea-related excessive sleepiness, and shift work sleep disorder. It affects several arousal systems, including dopamine, orexin, norepinephrine, histamine, and glutamate pathways, while generally producing a different pharmacological profile from amphetamine stimulants.
For broader research context on nootropic compounds, including comparative stacks, cycling considerations, and interaction notes, see the Complete Nootropic Cheat Sheet.
What Is Modafinil?
Modafinil is a wakefulness-promoting medicine classified as a eugeroic, a term referring to agents that promote alertness with comparatively limited broad-spectrum stimulation. It is approved by the United States Food and Drug Administration for excessive sleepiness associated with narcolepsy, obstructive sleep apnea or hypopnea syndrome, and shift work sleep disorder. In obstructive sleep apnea, it is intended as an adjunct to treatment of the underlying airway obstruction, such as continuous positive airway pressure, rather than as a replacement for definitive respiratory therapy. Modafinil is commonly supplied as an oral tablet, with typical clinical use involving once-daily administration under medical supervision.
The compound was developed in France during research into drugs related to the older stimulant adrafinil and was subsequently developed internationally by Lafon Laboratories. In the United States, modafinil is classified as a Schedule IV controlled substance because it has recognized medical value but also carries potential for misuse, psychological dependence, and diversion. Brand names have included Provigil, Modalert, Modvigil, and Alertec, although availability and regulatory status vary by country. Modafinil is not an over-the-counter supplement, and products sold through unregulated websites may contain incorrect doses, contaminants, or different active ingredients.
Research Indications
Wakefulness Disorders
Narcolepsy-Associated Sleepiness
Randomized controlled trials support modafinil for improving objectively and subjectively measured daytime wakefulness in narcolepsy.
Residual Sleepiness in Obstructive Sleep Apnea
Used as an adjunct for residual excessive daytime sleepiness in appropriately treated obstructive sleep apnea; it does not replace airway therapy.
Shift Work Sleep Disorder
Clinical studies support improved wakefulness during scheduled night work in people with diagnosed shift work sleep disorder.
Cognition Under Sleep Loss
Sustained Attention During Sleep Deprivation
Laboratory and operational research indicates benefit for vigilance and alertness when performance is impaired by acute sleep deprivation.
Executive Function and Working Memory
Effects in rested healthy adults are variable, with systematic reviews finding modest task-dependent improvements rather than universal enhancement.
Mood and Psychiatric Adjunct Research
Depression-Related Fatigue
Adjunctive studies have examined fatigue and residual symptoms in major depression, but results are mixed and use requires psychiatric oversight.
Attention-Deficit/Hyperactivity Disorder
Trials have explored modafinil in ADHD, but it is not broadly approved for this indication and safety considerations limit routine use.
Neuroprotection and Fatigue States
Neurologic Disease Fatigue
Research in fatigue associated with neurologic conditions has produced heterogeneous findings and does not establish a general therapeutic role.
Mechanistic Neuroprotection Studies
Preclinical work suggests effects on catecholamine, histamine, orexin, and glutamatergic systems; these findings are not proof of clinical neuroprotection.
Research Protocols
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
| Research Application | Dose | Frequency | Route |
|---|
| Narcolepsy-related sleepiness | 200 mg | Once daily, morning | Oral |
| Residual sleepiness in OSA | 200 mg | Once daily, morning | Oral |
| Shift work sleep disorder | 200 mg | Once, about 1 hour before shift | Oral |
| Healthy-volunteer cognition studies | 100–200 mg | Single experimental dose | Oral |
Timing
Morning administration is used for daytime sleepiness. For night-shift protocols, published labeling uses dosing approximately 1 hour before the work shift. Avoid late-day dosing because wake-promoting effects may delay sleep onset.
Peptide Interactions
May add to insomnia, anxiety, tremor, palpitations, and blood-pressure elevation; reduce total stimulant load.
Combining wake-promoting and sympathomimetic stimulants can increase cardiovascular and psychiatric adverse-effect risk unless specifically managed by a prescriber.
Modafinil can induce CYP3A4 and may reduce the effectiveness of steroidal contraceptives; use reliable alternative or backup contraception as directed by a clinician.
Potential metabolic interaction warrants closer INR monitoring when modafinil is started, stopped, or dose-adjusted.
Inhibition of CYP2C19 may increase exposure to diazepam and certain other CYP2C19 substrates.
Armodafinil is the R-enantiomer of modafinil; concurrent use duplicates pharmacologic exposure and is generally not appropriate.
Reported Research Timeline
0130–60 minutes: early wake-promoting effects may begin, although onset varies with food intake and individual metabolism.
022–4 hours: plasma concentrations approach peak; alertness and sustained-attention effects are commonly most noticeable in this window.
034–8 hours: wakefulness support can persist through much of the day; headache, reduced appetite, dry mouth, or anxiety may also become apparent.
0410–15 hours: the long effective half-life means clinically meaningful stimulation may remain; late dosing can interfere with planned sleep.
05Several days: assess sleep timing, mood, blood pressure, and whether the medication is masking inadequate sleep or untreated sleep-disordered breathing.
062–4 weeks: clinicians commonly reassess benefit, adverse effects, psychiatric symptoms, cardiovascular tolerability, and interacting medicines.
Safety Notes
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
Common adverse effects include headache, nausea, reduced appetite, nervousness, dry mouth, and insomnia.
Avoid late-day administration when possible; its long duration can worsen insomnia and impair recovery sleep.
Use caution with hypertension, arrhythmia, structural heart disease, anxiety disorders, psychosis, mania, or a history of stimulant-related adverse reactions.
Modafinil may alter metabolism of other medicines, including hormonal contraceptives, warfarin, and CYP2C19 substrates.
It is not a substitute for adequate sleep, treatment of obstructive sleep apnea, or evaluation of persistent daytime sleepiness.
Seek Medical Attention If:
A rash, blistering, mouth sores, facial swelling, fever, or other signs of a serious hypersensitivity reaction occur.
Chest pain, fainting, severe palpitations, marked shortness of breath, or sustained severe blood-pressure symptoms develop.
New hallucinations, mania, severe agitation, suicidal thoughts, or major mood or behavior changes appear.
Swelling of the face or throat, trouble breathing, yellowing of the skin or eyes, or severe persistent abdominal symptoms occur.
Quality Indicators
Verified Marker
Batch-Specific Certificate of Analysis
Look for an accessible COA tied to the exact lot number, with identity, assay, and impurity testing results.
Verified Marker
Independent HPLC or LC-MS Identity Testing
A credible report identifies modafinil using an appropriate analytical method and provides chromatographic or mass-spectrometric documentation.
Verified Marker
Third-Party Contaminant Screening
Verification should include heavy metals and relevant microbial or residual-solvent testing performed by an independent laboratory.
Acceptable Range
Accurate Capsule or Tablet Content
Finished-product testing should substantiate the labeled milligram amount and reasonable unit-to-unit dose uniformity.
Quality Concern
No Verifiable Lot Documentation
Avoid products with generic, undated, internally generated, or unverifiable purity claims, especially where prescription-only supply chains are bypassed.
Research Citations
- Modafinil for the treatment of pathological sleepiness in narcolepsy: a randomized, double-blind, placebo-controlled study
US Modafinil in Narcolepsy Multicenter Study Group, 2000, JAMA - Maintaining alertness and performance during sleep deprivation: modafinil versus caffeine
Wesensten, N. J., Belenky, G., Kautz, M. A., et al., 1999, JAMA - Modafinil as adjunct therapy for daytime sleepiness in obstructive sleep apnea
Pack, A. I., Black, J. E., Schwartz, J. R. L., Matheson, J. K., 2001, American Journal of Respiratory and Critical Care Medicine - Modafinil as a cognitive enhancer in healthy non-sleep-deprived subjects: a systematic review
Battleday, R. M., Brem, A. K., 2015, European Neuropsychopharmacology
Research Focus
wakefulness, orexin, dopamine, norepinephrine, cognitive enhancement, narcolepsy, shift work
Frequently Asked Questions
What should researchers watch for with Modafinil?
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
What should researchers expect over time with Modafinil?
30–60 minutes: early wake-promoting effects may begin, although onset varies with food intake and individual metabolism.
How is Modafinil typically administered in research?
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
Browse all peptides in the Encyclopedia →